Regarding primary prostate cancer, current research is focusing on the identification and accurate contouring of the intraprostatic tumor volume based on PSMA PET/CT in order to allow for focal radiation therapy with dose escalation to the PSMA PET-positive lesions within the prostatic gland [145, 146]. Here, FOLH1 is linked to prostate carcinoma.